Marker Therapeutics (NASDAQ:MRKR – Get Free Report) and Longeveron (NASDAQ:LGVN – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability and dividends.
Analyst Recommendations
This is a breakdown of recent recommendations for Marker Therapeutics and Longeveron, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Marker Therapeutics | 1 | 1 | 2 | 0 | 2.25 |
| Longeveron | 1 | 1 | 1 | 0 | 2.00 |
Marker Therapeutics currently has a consensus price target of $10.00, suggesting a potential upside of 866.18%. Longeveron has a consensus price target of $80.00, suggesting a potential upside of 3,200.33%. Given Longeveron’s higher possible upside, analysts plainly believe Longeveron is more favorable than Marker Therapeutics.
Earnings & Valuation
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Marker Therapeutics | $3.55 million | 4.86 | -$12.16 million | ($0.41) | -2.52 |
| Longeveron | $1.20 million | 6.44 | -$22.70 million | ($9.90) | -0.24 |
Marker Therapeutics has higher revenue and earnings than Longeveron. Marker Therapeutics is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.
Risk & Volatility
Marker Therapeutics has a beta of 1.53, meaning that its stock price is 53% more volatile than the S&P 500. Comparatively, Longeveron has a beta of -0.19, meaning that its stock price is 119% less volatile than the S&P 500.
Insider and Institutional Ownership
22.4% of Marker Therapeutics shares are held by institutional investors. Comparatively, 10.0% of Longeveron shares are held by institutional investors. 5.7% of Marker Therapeutics shares are held by company insiders. Comparatively, 7.4% of Longeveron shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Profitability
This table compares Marker Therapeutics and Longeveron’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Marker Therapeutics | N/A | -56.96% | -47.82% |
| Longeveron | -1,977.59% | -223.19% | -150.20% |
Summary
Marker Therapeutics beats Longeveron on 10 of the 14 factors compared between the two stocks.
About Marker Therapeutics
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.
About Longeveron
Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company’s lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer’s disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
Receive News & Ratings for Marker Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Marker Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
